SCHEMBL7189504

SCHEMBL7189504

CCC(C)[PH](=O)c1ccccc1C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSS P25774 6/20 0.39
CTSK P43235 2/20 0.38
POLB P06746 1/20 0.37
MAPK1 P28482 1/20 0.37
F2R P25116 1/20 0.36
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
CNR2 P34972 2/20 0.35
TAS2R14 Q9NYV8 1/20 0.34
KCNK3 O14649 1/20 0.34
KCNK9 Q9NPC2 1/20 0.34
RORC P51449 2/20 0.34
P2RX7 Q99572 1/20 0.34
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
EPHX2 P34913 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181406 0.81 TAS1R3 (0.39) LMNAGAACNR2RORCCYP3A4
SCHEMBL7187930 0.79 CA12 (0.40) LMNACNR2KCNK3KCNK9
SCHEMBL7183921 0.77 CTSS (0.33) CTSSCTSKF2RLMNAGAA
SCHEMBL7181405 0.77 KMT2A (0.39) LMNACYP2C9
SCHEMBL7186971 0.77 TP53 (0.32) MAPK1CYP3A4CYP2C9PPARG
SCHEMBL7175837 0.77 RORC (0.41) LMNAGAACNR2RORCCYP3A4
SCHEMBL7189803 0.76 ALDH1A1 (0.41) CTSSCTSKPOLBMAPK1F2R
SCHEMBL7188463 0.75 MEN1 (0.31)
SCHEMBL7189513 0.75 CTSS (0.39) CTSSCTSKPOLBMAPK1F2R
SCHEMBL7182252 0.74 TGM2 (0.40) LMNARORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 CTSS 4260/4885CTSK 3932/4885POLB 2322/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 CTSS 4218/4885CTSK 4138/4885POLB 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.